Personal information

No personal information available

Activities

Collapse all

Employment (4)

National Cancer Institute: Bethesda, Maryland, US

2014-11 to present | Research Fellow (Center for Cancer Research)
Employment
Source: Self-asserted source
Michael Beshiri

University of Illinois: Chicago, IL, US

2007-08 to 2014-04 | Graduate Student(PhD candidate) (Biochemistry and Molecular Genetics)
Employment
Source: Self-asserted source
Michael Beshiri

Tufts University Cummings School of Veterinary Medicine: North Grafton, MA, US

2001 to 2007 | Senior Research Technician (Department of Infectious Diseases)
Employment
Source: Self-asserted source
Michael Beshiri

University of Massachusetts Medical School: Worcester, Massachusetts, US

1999 to 2001 | Research Technician (Cancer Center)
Employment
Source: Self-asserted source
Michael Beshiri

Education and qualifications (2)

University of Illinois at Chicago: Chicago, IL, US

2014 | PhD (Biochemistry and Molecular Genetics)
Education
Source: Self-asserted source
Michael Beshiri

Assumption College : Worcester, Massachusetts, US

1999 | Bachelor of Arts (Biology)
Education
Source: Self-asserted source
Michael Beshiri

Professional activities (4)

National Postdoctoral Association: Washington D.C., District of Columbia, US

Membership
Source: Self-asserted source
Michael Beshiri

American Association for Cancer Research: Philadelphia, PA, US

2016 to present
Service
Source: Self-asserted source
Michael Beshiri

Prostate Cancer Foundation: Santa Monica, CA, US

2019 | Young Investigator Award
Distinction
Source: Self-asserted source
Michael Beshiri

National Institutes of Health: Bethesda , MD, US

2017 | Fellows Award for Research Excellence
Distinction
Source: Self-asserted source
Michael Beshiri

Funding (1)

Investigation of the Subpopulation Dynamics of Treatment-Emergent Neuroendocrine Prostate Cancer Using Patient-Derived Organoids

2019-10 to 2022-09 | Award
Prostate Cancer Foundation (CA, CA, US)
GRANT_NUMBER: 19YOUN02
Source: Self-asserted source
Michael Beshiri

Works (12)

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer

2022-03-27 | Preprint
DOI: 10.1101/2022.03.24.484651
Contributors: Michael L. Beshiri; Brian J. Capaldo; Ross Lake; Anson T. Ku; Danielle Burner; Caitlin M. Tice; Crystal Tran; Julianna Kostas; Aian Neil Alilin; JuanJuan Yin et al.
Source: check_circle
Crossref

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.

Cell reports
2019-11-01 | Journal article
DOI: 10.1016/j.celrep.2019.10.068
PMID: 31747605
PMC: PMC6886683
Source: Self-asserted source
Michael Beshiri

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Clinical cancer research : an official journal of the American Association for Cancer Research
2019-08-13 | Journal article
DOI: 10.1158/1078-0432.CCR-19-0419
PMID: 31409613
PMC: PMC6801079
Source: Self-asserted source
Michael Beshiri

EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis.

Oncogene
2019-07-16 | Journal article
DOI: 10.1038/s41388-019-0873-8
PMID: 31312026
PMC: PMC6715537
Source: Self-asserted source
Michael Beshiri

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Journal for immunotherapy of cancer
2018-12-04 | Journal article
DOI: 10.1186/s40425-018-0463-2
PMID: 30514390
PMC: PMC6280368
Source: Self-asserted source
Michael Beshiri

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.

Scientific reports
2018-11-22 | Journal article
DOI: 10.1038/s41598-018-35417-0
PMID: 30467317
PMC: PMC6250716
Source: Self-asserted source
Michael Beshiri

A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-05-10 | Journal article
DOI: 10.1158/1078-0432.CCR-18-0409
PMID: 29748182
PMC: PMC6125202
Source: Self-asserted source
Michael Beshiri

Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer.

Oncotarget
2017-08-24 | Journal article
DOI: 10.18632/oncotarget.20424
PMID: 29100379
PMC: PMC5652772
Source: Self-asserted source
Michael Beshiri

Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.

Genes & development
2015-08-27 | Journal article
DOI: 10.1101/gad.264036.115
PMID: 26314709
PMC: PMC4573855
Source: Self-asserted source
Michael Beshiri

Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation.

Proceedings of the National Academy of Sciences of the United States of America
2012-10-23 | Journal article
DOI: 10.1073/pnas.1216724109
PMID: 23093672
PMC: PMC3494949
Source: Self-asserted source
Michael Beshiri

Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.

Proceedings of the National Academy of Sciences of the United States of America
2011-07-25 | Journal article
DOI: 10.1073/pnas.1110104108
PMID: 21788502
PMC: PMC3158206
Source: Self-asserted source
Michael Beshiri

Genome-wide analysis using ChIP to identify isoform-specific gene targets.

Journal of visualized experiments : JoVE
2010-07-07 | Journal article
DOI: 10.3791/2101
PMID: 20644511
PMC: PMC3156076
Source: Self-asserted source
Michael Beshiri
How many people are using ORCID?